Lentivirus Pseudotyped with SARS-CoV-2 Spike Glycoprotein, South Africa Variant

Catalog #: EG-342

Qty:

Product Name	Lentivirus Pseudotyped with SARS-CoV-2 Spike Glycoprotein, HexaPro Stabilized Trimer, South Africa Variant
Description	Lentivirus particles pseudotyped with SARS‑CoV‑2 spike glycoprotein, with hexaPro mutations so the surface protein antigenically optimal pre-fusion conformation, produced and purified from HEK 293 cells. The Sounth African has these mutations: K417N, E484K and N501Y.
Mutations	Furin site RRAR mutated to GSAS; HexaPro mutations (K986P, V987P, F817P, A892P, A899P and A942P) to ensure the S glycoprotein remains in an antigenically optimal pre-fusion conformation; Sounth African mutations: K417N, E484K and N501Y
Source	HEK293T cells
Reporter	EGFP
Application	Screening of SARS‑CoV‑2 neutralizing antibodies Assessment of vaccine efficacy
Titer	> 1 X 10⁷ RFU/ml or > 1 X 10⁵ TU/ml
Shipping	Dry ice
Storage	-80 oC
References	Efective screening of SARS‑CoV‑2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS‑CoV‑2 spike glycoprotein. Sci Rep 10, 19076 (2020). doi:10.1038/s41598-020-76135-w Prospective Mapping of Viral Mutations that Escape Antibodies Used to Treat COVID-19. Science. 371 (2020): 850-854. doi: 10.1126/science.abf9302. PubMed: 33495308.

Home \| Privacy Policy \| Terms & Conditions \| Online Price Policy \| Shipping & Return